Oryzon genomics floats on the MAB

, ,
Integral service around a transaction
BY : Diego GutiérrezDecember Thu, 2015

Oryzon Genomics is now listed on the MAB, reinforcing the biotech market, which is the largest listed on the MAB. Of the 33 companies listed on the MAB, 8 are active in the biotechnology sector.


Oryzon Genomics' listing on the MAB

 It was floated on the Mab on Monday 14 December, through a listing process at a price of 3.39 euros per share.

Shares in biotech company Oryzon soared 32% on its debut on the Continuous Market on Monday, as it hit a price of 4.49 euros per share, compared to the 3.39 euros set at its initial public offering, and subsequently the gain soared to almost 55% after touching 5.25 euros.

Oryzon's debut on the stock market is the end of a long career. As we have already mentioned in previous posts, the company had been considering different possibilities for some time, such as going public on the MAB or the Nasdaq. Finally, they have decided to consolidate on the continuous market, after a long period of capital increase 16.5m and then move to the American market.

The company specialises in epigenetics for oncology and neurodegenerative diseases. Its revenues depend on the scientific milestones it achieves. For example, while in 2013 the company's turnover was 43,786 euros, in 2014 it shot up to 13.1 million euros after signing an agreement with the multinational Roche for its drug ORY-1001. This year, the company will reach a turnover of 3.5 million euros after achieving a scientific milestone within the agreement with the Swiss group.

The biotechnology sector on the MAB

mab bio

After 2 years in which no biotech company had been listed on the MAB, 2015 has been the year of recovery of the sector with the incorporation of 2 companies, Neol Bio and the recently mentioned Oryzon genomics.

Among the 8 companies listed on the MAB, the size of capitalisation varies widely, ranging from companies such as Euroespes which has a market capitalisation size of €4M to companies such as Oryzon which has a market capitalisation size of €96M.

Euroespes is a Galician company, the first private company dedicated exclusively to the research, diagnosis and treatment of diseases of the central nervous system (CNS).

EuroEspespes, obtained in 2014 an EBITDA of €454,000, 78% more than the previous year. According to the data submitted to the MAB, last year the company's gross margin improved by 12.7% on a turnover of €2.57M and the net result was six times higher than in 2013.

In terms of share price, the recently mentioned Euroespes is the company that has grown the most in 2015. Bionaturis is the company whose capitalisation fell the most in 2015, by 48%.

In November , Bionaturis announced  that the Board of Directors of the company unanimously resolved to rescind in its entirety the resolution of capital increase adopted at its meeting of 14 May 2015.

Bionaturis is currently looking for alternatives to finance the acquisition of the pharmaceutical CMO it intended to acquire.

 This week we have known that (CDTI) has awarded Bionaturis through the Eurostars programme, a grant of 184,847.40€ for its participation in the CERVI PRO initiative.

Another MAB biotech company, Inkemia, has been in the news these days for acquiring two families of patents derived from the "2G Biofuel" project. The patents are related to the development of second-generation biofuels and new biofuels for industrial boilers Heating BioOil

If you are looking for financing please contact us, Abra-Invest has an expert team in alternative financing at your disposal. Fill in the contact form or call us on + 34 946424142

Other posts that may interest you

The MAB, alternative financing that is making a comeback

October 2015: Funding for the biotech sector: InnoUp Farma and Oryzon Genomics and Mind The Byte

Spanish biotech companies go public

The M&A Professionals

Meet our services



Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?